Rein Therapeutics, Inc. SEC filings RNTX
Rein Therapeutics, Inc. has 525 filings in SEC EDGAR's recent list, going back to Dec 3, 2007. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 4, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 27, 2026 | Aug 21, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jul 21, 2026 | Jul 20, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 14, 2026 | — |
| ARS | Annual report to shareholders | Jun 8, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEF 14A | Proxy statement | Jun 8, 2026 | Jul 20, 2026 |
| 4 | Insider transaction | May 28, 2026 | May 21, 2026 |
| PRE 14A | Preliminary proxy statement | May 28, 2026 | Jul 20, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | May 13, 2026 | Apr 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 8, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 8, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 7, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 6, 2026 | — |
| 8-K |
Current report
Material agreement, Other events
|
May 4, 2026 | Apr 30, 2026 |
| 424B5 | Prospectus supplement | May 4, 2026 | — |
| EFFECT | Filing | Apr 30, 2026 | — |
| CORRESP | Letter to the SEC | Apr 28, 2026 | — |
| CORRESP | Letter to the SEC | Apr 28, 2026 | — |
| S-1 | Registration statement | Apr 28, 2026 | — |
| 10-K/A | Amended annual report | Apr 27, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Mar 2, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 19, 2026 | Feb 16, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jan 16, 2026 | Jan 15, 2026 |
| UPLOAD | Letter from the SEC | Dec 31, 2025 | — |
| DRS | Filing | Dec 29, 2025 | — |
| 8-K |
Current report
Agreement ended
|
Dec 11, 2025 | Dec 11, 2025 |
| 4 | Insider transaction | Nov 18, 2025 | Nov 14, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Other events
|
Nov 3, 2025 | Nov 3, 2025 |
| 4 | Insider transaction | Oct 28, 2025 | Oct 24, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 24, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Other events
|
Oct 9, 2025 | Oct 9, 2025 |
| 3 | Initial insider ownership | Oct 3, 2025 | Sep 24, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Sep 26, 2025 | — |
| 8-K |
Current report
Other events
|
Sep 22, 2025 | Sep 16, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 9, 2025 | Sep 8, 2025 |
| EFFECT | Filing | Sep 5, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2025 | — |
| S-1 | Registration statement | Sep 3, 2025 | — |
| 8-K |
Current report
Other events
|
Aug 19, 2025 | Aug 19, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 30, 2025 | Jul 29, 2025 |
| 424B5 | Prospectus supplement | Jul 30, 2025 | — |
| 424B5 | Prospectus supplement | Jul 30, 2025 | — |
| 4 | Insider transaction | Jul 23, 2025 | Jul 23, 2025 |
| 4 | Insider transaction | Jul 23, 2025 | Jul 23, 2025 |
| 4 | Insider transaction | Jul 23, 2025 | Jul 23, 2025 |
| 4 | Insider transaction | Jul 23, 2025 | Jul 23, 2025 |
| 4 | Insider transaction | Jul 23, 2025 | Jul 23, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 23, 2025 | Jul 23, 2025 |
| DEFA14A | Additional proxy material | Jul 11, 2025 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jul 11, 2025 | Jul 8, 2025 |
| DEFA14A | Additional proxy material | Jun 24, 2025 | — |
| 8-K |
Current report
Other events
|
Jun 24, 2025 | Jun 24, 2025 |
| 8-K |
Current report
Other events
|
Jun 12, 2025 | Jun 10, 2025 |
| EFFECT | Filing | May 22, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 21, 2025 | — |
| S-3 | Shelf registration | May 16, 2025 | — |
| 8-K |
Current report
Results of operations
|
May 15, 2025 | May 15, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 424B5 | Prospectus supplement | May 15, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 14, 2025 | — |
| ARS | Annual report to shareholders | May 12, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| DEF 14A | Proxy statement | May 12, 2025 | Jun 24, 2025 |
| 10-K/A | Amended annual report | Apr 30, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 22, 2025 | Apr 21, 2025 |
| 8-K |
Current report
Auditor change
|
Apr 17, 2025 | Apr 16, 2025 |
| 10-K | Annual report | Apr 7, 2025 | Dec 31, 2024 |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jan 10, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Dec 9, 2024 | Dec 5, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 2, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 2, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 2, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 2, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 2, 2024 |
| 4 | Insider transaction | Dec 4, 2024 | Dec 2, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 5, 2024 | — |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Aug 21, 2024 | Aug 20, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 26, 2024 | Jul 26, 2024 |
| 424B5 | Prospectus supplement | Jul 26, 2024 | — |
| 424B5 | Prospectus supplement | Jul 26, 2024 | — |
| ARS | Annual report to shareholders | Jul 9, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Jul 9, 2024 | — |
| DEF 14A | Proxy statement | Jul 9, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 12, 2024 | Jun 10, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Other events
|
Jun 5, 2024 | Jun 5, 2024 |
| 3 | Initial insider ownership | May 16, 2024 | May 16, 2024 |
| 8-K |
Current report
Officer or director change
|
May 16, 2024 | May 15, 2024 |
| 8-K |
Current report
Results of operations
|
May 15, 2024 | May 15, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 4/A | Primary document | May 14, 2024 | May 1, 2024 |
| 4 | Insider transaction | May 1, 2024 | May 1, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
May 1, 2024 | May 1, 2024 |
| 424B5 | Prospectus supplement | May 1, 2024 | — |
| S-8 | Employee stock plan registration | May 1, 2024 | — |
| FWP | Free writing prospectus | May 1, 2024 | — |
| 8-K |
Current report
Results of operations, Other events
|
May 1, 2024 | May 1, 2024 |
| 3 | Initial insider ownership | Apr 30, 2024 | Feb 28, 2024 |
| 144 | Notice of proposed sale | Apr 29, 2024 | — |
| 10-K/A | Amended annual report | Apr 29, 2024 | Dec 31, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 16, 2024 | — |
| 8-K |
Current report
Results of operations
|
Apr 15, 2024 | Apr 15, 2024 |
| 10-K | Annual report | Apr 15, 2024 | Dec 31, 2023 |
| 4/A | Filing | Apr 10, 2024 | Feb 28, 2024 |
| 4/A | Filing | Apr 10, 2024 | Feb 28, 2024 |
| 3 | Initial insider ownership | Apr 2, 2024 | Mar 25, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 29, 2024 | Mar 25, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 15, 2024 | Mar 11, 2024 |
| 4 | Insider transaction | Mar 6, 2024 | Mar 5, 2024 |
| SC 13G | Ownership over 5% (passive) | Mar 5, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 5, 2024 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Mar 1, 2024 | Feb 29, 2024 |
| 4 | Insider transaction | Mar 1, 2024 | Feb 28, 2024 |
| 4 | Insider transaction | Mar 1, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Feb 29, 2024 | Feb 28, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Feb 13, 2024 | Feb 9, 2024 |
| EFFECT | Filing | Feb 5, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 1, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2024 | — |
| DEFA14A | Additional proxy material | Jan 31, 2024 | — |
| S-8 | Employee stock plan registration | Jan 29, 2024 | — |
| S-3 | Shelf registration | Jan 29, 2024 | — |
| ARS | Annual report to shareholders | Jan 29, 2024 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Jan 29, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Other events
|
Jan 29, 2024 | Jan 29, 2024 |
| 8-K |
Current report
Other events
|
Jan 25, 2024 | Jan 25, 2024 |
| PRE 14A | Preliminary proxy statement | Jan 19, 2024 | Jan 19, 2024 |
| 8-K/A | Amended current report | Jan 11, 2024 | Oct 30, 2023 |
| 8-K |
Current report
Listing notice, Auditor change
|
Jan 10, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Dec 18, 2023 | Dec 15, 2023 |
| 4 | Insider transaction | Nov 21, 2023 | Nov 20, 2023 |
| D | Filing | Nov 16, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Nov 13, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 3, 2023 | — |
| 4 | Insider transaction | Nov 2, 2023 | Oct 31, 2023 |
| 4 | Insider transaction | Nov 2, 2023 | Oct 31, 2023 |
| 3 | Initial insider ownership | Nov 2, 2023 | Oct 31, 2023 |
| 3 | Initial insider ownership | Nov 2, 2023 | Oct 31, 2023 |
| 3 | Initial insider ownership | Nov 2, 2023 | Oct 31, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Auditor change, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 31, 2023 | Oct 30, 2023 |
| 10-Q | Quarterly report | Oct 13, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 8, 2023 | Mar 31, 2023 |
| 10-K/A | Amended annual report | Apr 28, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 20, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Feb 23, 2023 | Feb 16, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Nov 10, 2022 | Nov 10, 2022 |
| 10-Q | Quarterly report | Nov 1, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Officer or director change
|
Jul 8, 2022 | Jul 8, 2022 |
| 8-K |
Current report
Other events
|
Jun 29, 2022 | Jun 29, 2022 |
| 424B5 | Prospectus supplement | Jun 21, 2022 | — |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 3 | Initial insider ownership | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2022 |
| 4 | Insider transaction | Jun 17, 2022 | Jun 15, 2020 |
| EFFECT | Filing | Jun 16, 2022 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2022 | Jun 15, 2022 |
| CORRESP | Letter to the SEC | Jun 14, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2022 | — |
| DEL AM | Filing | Jun 13, 2022 | — |
| 8-K |
Current report
Listing notice
|
Jun 8, 2022 | Jun 7, 2022 |
| S-3 | Shelf registration | Jun 8, 2022 | — |
| 8-K |
Current report
Officer or director change
|
Jun 7, 2022 | Jun 5, 2022 |
| 10-Q | Quarterly report | May 5, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 29, 2022 | Apr 25, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2022 | Jun 15, 2022 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc. (until Dec 9, 2024); AILERON THERAPEUTICS INC (until Mar 29, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.